Literature DB >> 25403343

Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers.

Ghada F Ahmed1, Susan E Marino, Richard C Brundage, Serguei V S Pakhomov, Ilo E Leppik, James C Cloyd, Annie Clark, Angela K Birnbaum.   

Abstract

AIMS: The aim was to develop a quantitative approach that characterizes the magnitude of and variability in phonemic generative fluency scores as measured by the Controlled Oral Word Association (COWA) test in healthy volunteers after administration of an oral and a novel intravenous (IV) formulation of topiramate (TPM).
METHODS: Nonlinear mixed-effects modelling was used to describe the plasma TPM concentrations resulting from oral or IV administration. A pharmacokinetic-pharmacodynamic (PK-PD) model was developed sequentially to characterize the effect of TPM concentrations on COWA with different distributional assumptions.
RESULTS: Topiramate was rapidly absorbed, with a median time to maximal concentration of 1 h and an oral bioavailability of ~100%. Baseline COWA score increased by an average of 12% after the third administration on drug-free sessions. An exponential model described the decline of COWA scores, which decreased by 14.5% for each 1 mg l(-1) increase in TPM concentration. The COWA scores were described equally well by both continuous normal and Poisson distributions.
CONCLUSIONS: This analysis quantified the effect of TPM exposure on generative verbal fluency as measured by COWA. Repetitive administration of COWA resulted in a better performance, possibly due to a learning effect. The model predicts a 27% reduction in the COWA score at the average observed maximal plasma concentration after a 100 mg dose of TPM. The single-dose administration of relatively low TPM doses and narrow range of resultant concentrations in our study were limitations to investigating the PK-PD relationship at higher TPM exposures. Hence, the findings may not be readily generalized to the broader patient population.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  modelling; pharmacodynamics; pharmacokinetics; topiramate; verbal fluency

Mesh:

Substances:

Year:  2015        PMID: 25403343      PMCID: PMC4415718          DOI: 10.1111/bcp.12556

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Pharmacokinetics and pharmacodynamics of topiramate.

Authors:  B F Bourgeois
Journal:  J Child Neurol       Date:  2000       Impact factor: 1.987

2.  A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures.

Authors:  A P Aldenkamp; G Baker; O G Mulder; D Chadwick; P Cooper; J Doelman; R Duncan; C Gassmann-Mayer; G J de Haan; C Hughson; J Hulsman; J Overweg; G Pledger; T W Rentmeester; H Riaz; S Wroe
Journal:  Epilepsia       Date:  2000-09       Impact factor: 5.864

3.  Topiramate dose effects on cognition: a randomized double-blind study.

Authors:  D W Loring; D J Williamson; K J Meador; F Wiegand; J Hulihan
Journal:  Neurology       Date:  2010-12-09       Impact factor: 9.910

4.  A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy.

Authors:  Tomaz Vovk; Mihajlo B Jakovljević; Mojca Kerec Kos; Slobodan M Janković; Ales Mrhar; Iztok Grabnar
Journal:  Biol Pharm Bull       Date:  2010       Impact factor: 2.233

5.  The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory.

Authors:  S E Marino; S V S Pakhomov; S Han; K L Anderson; M Ding; L E Eberly; D W Loring; C Hawkins-Taylor; J O Rarick; I E Leppik; J E Cibula; A K Birnbaum
Journal:  Epilepsy Behav       Date:  2012-05-30       Impact factor: 2.937

6.  Clinical pharmacology of topiramate: a review.

Authors:  W R Garnett
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

7.  Genetic and environmental correlates of topiramate-induced cognitive impairment.

Authors:  Elizabeth T Cirulli; Thomas J Urban; Susan E Marino; Kristen N Linney; Angela K Birnbaum; Chantal Depondt; Deborah K Attix; Rodney A Radtke; David B Goldstein
Journal:  Epilepsia       Date:  2011-11-16       Impact factor: 5.864

8.  Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy.

Authors:  M D Privitera; M J Brodie; R H Mattson; D W Chadwick; W Neto; S Wang
Journal:  Acta Neurol Scand       Date:  2003-03       Impact factor: 3.209

9.  A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy.

Authors:  F G Gilliam; F Veloso; M A M Bomhof; S K Gazda; V Biton; J P Ter Bruggen; W Neto; C Bailey; G Pledger; S-C Wu
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

10.  Differential cognitive and behavioral effects of topiramate and valproate.

Authors:  K J Meador; D W Loring; J F Hulihan; M Kamin; R Karim
Journal:  Neurology       Date:  2003-05-13       Impact factor: 9.910

View more
  4 in total

1.  Pharmacokinetic-Pharmacodynamic Modeling of Intravenous and Oral Topiramate and Its Effect on the Symbol-Digit Modalities Test in Adult Healthy Volunteers.

Authors:  Chay Ngee Lim; Angela K Birnbaum; Richard C Brundage; Ilo E Leppik; James C Cloyd; Annie Clark; Susan E Marino
Journal:  J Clin Pharmacol       Date:  2015-12-21       Impact factor: 3.126

2.  Severity of Topiramate-Related Working Memory Impairment Is Modulated by Plasma Concentration and Working Memory Capacity.

Authors:  Samuel P Callisto; Sílvia M Illamola; Angela K Birnbaum; Christopher M Barkley; Sai Praneeth R Bathena; Ilo E Leppik; Susan E Marino
Journal:  J Clin Pharmacol       Date:  2020-04-16       Impact factor: 3.126

Review 3.  Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders.

Authors:  Michael J Marmura; Aliza S Kumpinsky
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

Review 4.  Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet.

Authors:  Michael A Rogawski; Wolfgang Löscher; Jong M Rho
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.